| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.vistapharmaceuticals.com | |
| Market Cap | 37.75 Cr. | |
| Enterprise Value(EV) | 50.15 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.18 | Trailing Twelve Months Ending 2022-09 |
| Price-Earning Ratio (PE) | 58.62 | Trailing Twelve Months Ending 2022-09 |
| Industry PE | 30.86 | Trailing Twelve Months Ending 2022-09 |
| Book Value / Share | 9.37 | Trailing Twelve Months Ending 2022-09 |
| Price to Book Value | 1.10 | Calculated using Price: 10.26 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 3.68 Cr. | 36,793,907 Shares |
| FaceValue | 2 | |
| Company Profile | ||
| Vista Pharmaceuticals Limited was incorporated on January 25,1991 under the Companies Act of 1956 with the Registrar of Companies Andhra Pradesh & has obtained Certificate of Commencement of Business on February 7, 1991. Vista Pharmaceuticals was incorporated by Dr. Dhananjaya Alli & his associates. The capital was subscribed by Vista Pharmaceuticals Inc., an Overseas Corporate Body promoted by them as a per the laws of State of New Jersy, United States of America. | ||
| 1 Day |
|
+0.10% |
| 1 Week |
|
+0.10% |
| 1 Month |
|
-17.29% |
| 3 Month |
|
+29.87% |
| 6 Month |
|
+48.15% |
| 1 Year |
|
-25.82% |
| 2 Year |
|
+5.49% |
| 5 Year |
|
-76.16% |
| 10 Year |
|
+90.84% |
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 5.27 | 13.94 | 7.15 | 8.97 | 10.19 | 3.15 | -11.68 | -6.43 | -2.44 | |
| Return on Capital Employed (%) | 5.38 | 14.16 | 9.57 | 8.92 | 12.42 | 6.28 | -5.20 | -5.10 | -3.63 | |
| Return on Assets (%) | 3.27 | 7.39 | 3.15 | 3.70 | 4.67 | 1.78 | -7.11 | -3.89 | -1.59 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 9 | 10 | 11 | 17 | 32 | 36 | 30 | 33 | 35 | 34 | |
| Non Curr. Liab. | 0 | 0 | 8 | 5 | 6 | 6 | 5 | 11 | 6 | 5 | |
| Curr. Liab. | 5 | 12 | 7 | 19 | 15 | 11 | 16 | 9 | 11 | 12 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 14 | 23 | 26 | 41 | 53 | 53 | 51 | 53 | 52 | 52 | |
| Non Curr. Assets | 12 | 11 | 10 | 16 | 25 | 29 | 30 | 37 | 37 | 36 | |
| Curr. Assets | 2 | 12 | 16 | 26 | 28 | 23 | 21 | 15 | 15 | 16 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 14 | 23 | 26 | 41 | 53 | 53 | 51 | 53 | 52 | 52 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
| Net Sales | 8 | 14 | 15 | 24 | 29 | 31 | 23 | 1 | 0 | 0 | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 0 | 0 | 0 | |
| Total Income | 8 | 14 | 15 | 24 | 29 | 34 | 27 | 1 | 1 | 0 | |
| Total Expenditure | -7 | -11 | -13 | -21 | -24 | -30 | -28 | -3 | -2 | -1 | |
| PBIDT | 1 | 3 | 3 | 3 | 6 | 4 | -1 | -2 | -1 | -1 | |
| Interest | 0 | -1 | -1 | -2 | -2 | -2 | -2 | -1 | -1 | ||
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 2 | 2 | 3 | |
| Exceptional Items | |||||||||||
| PAT | 0 | 1 | 1 | 1 | 2 | 1 | -4 | -2 | -1 | 1 | |
| Adjusted EPS | 0 | 1 | 0 | 0 | 1 | 0 | -1 | -1 | 0 | 0 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | -4 | -3 | 3 | -5 | 3 | 1 | -7 | -1 | |
| Cash Fr. Inv. | 0 | 0 | 0 | 0 | -4 | -11 | -6 | -2 | 0 | 0 | |
| Cash Fr. Finan. | 0 | 4 | 3 | 6 | 11 | 1 | 0 | 7 | 1 | ||
| Net Change | 0 | 0 | 0 | 5 | -4 | -1 | -1 | 0 | 0 | ||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 6 | 2 | 1 | 0 | 0 | 0 |
|
Tue, 07 Feb 2023
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 13.02.2023. VISTA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023 inter alia to consider and approve With reference to the subject cited the meeting of the Board of Directors of the Company M/s. Vista Pharmaceuticals Limited will be held on Monday 13.02.2023 at 04.00 P.M at the Corporate office of the Company Situated at 7-1-212/A/70 1st Floor Plot No. 85 Shivbagh Ameerpet Hyderabad- 500016 Telangana inter-alia to discuss the following:1. To consider approve and take on record the un-audited Financial Results of the company for the quarter ended 31st December 2022.2. To consider and take note of Limited Review Report for the quarter ended 31st December 2022.3. Any other items with permission of chairman. |
|
Fri, 20 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 With reference to the above-mentioned subject matter please find enclosed herewith certificate issued by Aarthi Consultants Private Limited Registrar and Share Transfer Agent confirming the compliance of regulation 74 (5) of SEBI (Depository and Participants) Regulations 2018 for the period from 01.10.2022 to 31.12.2022. |
|
Sat, 31 Dec 2022
Closure of Trading Window Notice is hereby given that in compliance with Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 read with SEBI (Prohibition of insider Trading) Regulations 2015 as amended from time to time the Company has intimated to all its Directors Key Management Personnel and Designated Employees regarding the Closure of the Trading Window of the Company from 01/01/2023 till 48 hours from the declaration of Financial Result for the quarter ended 31st December 2022.This closure of the Trading Window is occasioned by reason of declaration of financial results for the quarter ended 31st December 2022.All the insiders and their immediate relatives are hereby advised to take notice that in terms of trading restrictions placed under above regulations the Trading Window for the equity shares of the Company shall remain closed from 01/01/2023 till 48 hours after the declaration of the financial results for the quarter ended 31st December 2022. |
| Wed, 08 Feb 2023 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Close Crossing Last Month Close From Below
|
Making Lower Lows for 3 days
|
Equities
M.F.
Sectors